Back to top
more

Novavax (NVAX)

(Delayed Data from NSDQ)

$11.99 USD

11.99
4,400,799

+0.03 (0.25%)

Updated Aug 23, 2024 03:59 PM ET

After-Market: $11.96 -0.03 (-0.25%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Assertio (ASRT) to Report Q1 Earnings: What's in the Cards?

On Assertio Holdings' (ASRT) Q1 earnings call, investors will focus on the sales performance of its marketed products.

Novavax (NVAX) Starts COVID-19 Booster Study in Adolescents

Novavax's (NVAX) begins administering a third/booster dose of its COVID-19 vaccine in adolescents aged between 12 years and 17 years in a pivotal late-stage study.

Sanghamitra Saha headshot

Time for Reopening-Friendly Travel & Leisure ETFs?

As the pandemic is slowly turning into an endemic, leisure and travel stocks have flied higher.

Novavax (NVAX) Posts Upbeat Data on COVID/Flu Combo Jab Study

Results from Novavax's (NVAX) phase I/II study, which is evaluating a combination of its COVID-19 vaccine and the seasonal influenza vaccine candidate, demonstrate the combo vaccine's feasibility.

Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Novavax (NVAX) closed at $54.59, marking a -1.03% move from the previous day.

Novavax (NVAX) COVID Jab Gets Nod for Use in Switzerland

Novavax's (NVAX) Nuvaxovid is the first protein COVID-19 vaccine authorized for use in Switzerland. The stock price rises following the announcement.

Novavax (NVAX) Gains As Market Dips: What You Should Know

Novavax (NVAX) closed the most recent trading day at $60.63, moving +1.9% from the previous trading session.

Is Most-Watched Stock Novavax, Inc. (NVAX) Worth Betting on Now?

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Novavax (NVAX) Seeks EU Nod for COVID-19 Vaccine in Kids

Novavax (NVAX) seeks label expansion for its COVID-19 vaccine in adolescents aged 12-17 years in the European Union. Currently, the vaccine is authorized for use in adults.

Novavax (NVAX) Stock Moves -1.47%: What You Should Know

In the latest trading session, Novavax (NVAX) closed at $73.65, marking a -1.47% move from the previous day.

Why Is Novavax (NVAX) Down 5.9% Since Last Earnings Report?

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Novavax (NVAX) closed at $81.45, marking a +1.58% move from the previous day.

Moderna (MRNA) to File EUA for Use of mRNA-1273 in Children

Moderna's (MRNA) COVID-19 vaccine, mRNA-1273, generates robust neutralizing antibody response in a phase II/III study evaluating it in children.

Novavax's (NVAX) COVID Jab Gets EUA Nod for Kids in India

Novavax's (NVAX) COVID-19 vaccine receives its first authorization for emergency use in adolescents aged 12 years and above in India.

Pfizer (PFE) Gets Breakthrough Therapy Status for RSV Vaccine

Pfizer (PFE) is developing an RSV vaccine candidate, RSVpreF, to immunize pregnant women or older adults. The FDA grants a breakthrough therapy tag for the candidate's use in pregnant women.

Novavax's (NVAX) Q4 Loss Wider Than Expected, 2022 View Weak

Novavax (NVAX) reports a wider-than-expected loss for the fourth quarter of 2021. Also, revenues miss estimates. Its shares decline in after-market trading following the announcement.

Novavax (NVAX) Reports Q4 Loss, Misses Revenue Estimates

Novavax (NVAX) delivered earnings and revenue surprises of -681.82% and 42.37%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Daniel Laboe headshot

Time To Buy The Fear Dip?

Innovation's capitulation may be sold out as high-growth bears run out of selling fuel, leaving the door wide open for stock pickers to get into their favorite next-gen stocks

Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?

On Novavax's (NVAX) fourth-quarter earnings call, investor focus is likely to be on the initial sales numbers of the company's COVID-19 vaccine.

Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

Novavax (NVAX) closed the most recent trading day at $86.55, moving -0.67% from the previous trading session.

Pfizer (PFE) Plans to Delay Comirnaty for Kids EUA Submission

Pfizer (PFE) and its partner BioNTech are planning to extend their rolling submission to the FDA for the authorization of Comirnaty for use in children 6 months through 4 years of age to include the three-dose data.

Novavax's (NVAX) COVID Vaccine Achieves Study Goal in Kids

Novavax's (NVAX) COVID vaccine achieves 80% overall efficacy in a phase III study in adolescents aged between 12 and 17.

Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know

Novavax (NVAX) closed the most recent trading day at $95.18, moving +1.58% from the previous trading session.

Novavax's (NVAX) Shares Rise on FDA Filing for COVID Jab

After a series of delays, Novavax (NVAX) finally files a regulatory application with the FDA seeking emergency use authorization of its COVID-19 vaccine.

Novavax (NVAX) Stock Rises on Deal for COVID-19 Jab in Israel

Novavax (NVAX) enters into a supply agreement for its COVID-19 vaccine candidate, NVX-CoV2373, with Israel's Ministry of Health. Shares rise.